An efficient method of producing purified extracellular vesicles (EVs), in conjunction with a method that blocks liver macrophages from clearing EVs from the body, has produced promising results for the use of EVs in cancer therapy.

In the past, nonhuman primate research has relied on only a few infectious molecular clones for numerous diverse research projects including pathogenesis, preclinical vaccine evaluations, transmissions, and host vs. pathogen interactions. But new data suggests that there is a selected phenotype of the simian immunodeficiency virus (SIV) that causes infection.

Each year, two Student Poster Days—one at the NCI at Frederick campus and one on the Bethesda campus—give students a chance to showcase the work they do in NCI and NIH labs and offices. NCI at Frederick’s event was held in the Building 549 lobby, while the Bethesda poster day was held at the Natcher Conference Center in Building 45 on NIH’s main campus.

The NCI Technology Transfer Center (TTC) facilitates partnerships between NIH research laboratories and external partners. With a team of technology transfer specialists, NCI TTC guides interactions from discovery to patenting, as well as from collaboration and invention development to licensing.

Over the past 12 months, we’ve grown accustomed to seeing Zika in the news. The virus has been linked to thousands of cases of microcephaly in Brazilian babies. Numerous countries, including the United States, have reported Zika-related deaths. And there is no vaccine available at this time. In the face of what has become a global health crisis, the Vaccine Research Center (VRC) at the NIH/National Institute of Allergy and Infectious Diseases (NIAID) responded to a call from Anthony Fauci, M.D., head, NIAID, to get a candidate vaccine into human trials by the summer of 2016.